PubRank

Jian Z Wang

Author PubWeight™ 40.82‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol 2009 1.76
2 Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer. Phys Med Biol 2004 1.63
3 Predicting outcomes in cervical cancer: a kinetic model of tumor regression during radiation therapy. Cancer Res 2010 1.59
4 Synergistic effects of hemoglobin and tumor perfusion on tumor control and survival in cervical cancer. Int J Radiat Oncol Biol Phys 2009 1.46
5 Serial therapy-induced changes in tumor shape in cervical cancer and their impact on assessing tumor volume and treatment response. AJR Am J Roentgenol 2006 1.28
6 Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer. Invest Radiol 2009 1.24
7 Behind EUD. Acta Oncol 2008 1.10
8 Stereotactic radiosurgery with or without whole brain radiotherapy for patients with a single radioresistant brain metastasis. Am J Clin Oncol 2010 1.06
9 Stereotactic body radiation therapy for oligometastases. Expert Rev Anticancer Ther 2009 1.06
10 Longitudinal changes in tumor perfusion pattern during the radiation therapy course and its clinical impact in cervical cancer. Int J Radiat Oncol Biol Phys 2009 1.02
11 Translating response during therapy into ultimate treatment outcome: a personalized 4-dimensional MRI tumor volumetric regression approach in cervical cancer. Int J Radiat Oncol Biol Phys 2009 1.00
12 Ultra-early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer. Cancer 2010 0.98
13 Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2005 0.96
14 Equivalence of the linear-quadratic and two-lesion kinetic models. Phys Med Biol 2002 0.92
15 Characterizing tumor heterogeneity with functional imaging and quantifying high-risk tumor volume for early prediction of treatment outcome: cervical cancer as a model. Int J Radiat Oncol Biol Phys 2011 0.90
16 Management of metastatic spinal cord compression. Expert Rev Anticancer Ther 2010 0.90
17 Brachytherapy management of the retroverted uterus using ultrasound-guided implant applicator placement. Brachytherapy 2005 0.90
18 Cranial nerve involvement in nasopharyngeal carcinoma: response to radiotherapy and its clinical impact. Ann Otol Rhinol Laryngol 2006 0.90
19 Stereotactic body radiation therapy for hepatocellular carcinoma. Discov Med 2010 0.89
20 Onset time of tumor repopulation for cervical cancer: first evidence from clinical data. Int J Radiat Oncol Biol Phys 2012 0.88
21 Hypofractionation regimens for stereotactic radiotherapy for large brain tumors. Int J Radiat Oncol Biol Phys 2008 0.88
22 Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations. Phys Med Biol 2003 0.87
23 When tumor repopulation starts? The onset time of prostate cancer during radiation therapy. Acta Oncol 2010 0.86
24 Stereotactic body radiation therapy for oligometastases. Discov Med 2010 0.83
25 Stereotactic body radiation therapy for spinal metastases. Discov Med 2010 0.83
26 Comparison of real-time intraoperative ultrasound-based dosimetry with postoperative computed tomography-based dosimetry for prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007 0.83
27 Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes. Discov Med 2010 0.82
28 A generalized linear-quadratic model incorporating reciprocal time pattern of radiation damage repair. Med Phys 2012 0.81
29 Stereotactic radiosurgery alone for patients with 1-4 radioresistant brain metastases. Med Oncol 2010 0.81
30 Temporal analysis of tumor heterogeneity and volume for cervical cancer treatment outcome prediction: preliminary evaluation. J Digit Imaging 2009 0.80
31 MRI for cervical cancer not only correlates with tumor hypoxia, but also predicts ultimate outcome: in regard to Lim et al. (Int J Radiat Oncol Biol Phys 2008;70:126-133). Int J Radiat Oncol Biol Phys 2008 0.79
32 Characterizing at-Risk Voxels by Using Perfusion Magnetic Resonance Imaging for Cervical Cancer during Radiotherapy. J Cancer Sci Ther 2012 0.78
33 Stereotactic body radiation therapy for nonpulmonary primary tumors. Expert Rev Anticancer Ther 2008 0.78
34 The effect of docetaxel (taxotere) on human gastric cancer cells exhibiting low-dose radiation hypersensitivity. Clin Med Oncol 2008 0.77
35 Fractionated grid therapy in treating cervical cancers: conventional fractionation or hypofractionation? Int J Radiat Oncol Biol Phys 2007 0.77
36 Reirradiation with stereotactic body radiotherapy: analysis of human spinal cord tolerance using the generalized linear-quadratic model. Future Oncol 2013 0.76
37 In regard to Hoppe et al. (Int J Radiat Oncol Biol Phys 2008;72:1283-1286). Int J Radiat Oncol Biol Phys 2009 0.76
38 Direct sagittal image registration and tumor delineation on sagittal magnetic resonance imaging sequences for image-guided brachytherapy of cervical cancer. Discov Med 2012 0.75
39 Reporting of true spinal cord dose is encouraged for stereotactic body radiation therapy for spinal tumors. In regard to Sahgal et al. (Int J Radiat Oncol Biol Phys 2010;77:548-553). Int J Radiat Oncol Biol Phys 2010 0.75
40 PET-CT for tumor delineation: in regard to Heron et al. (Int J Radiat Oncol Biol Phys 2004;60:1419-1424). Int J Radiat Oncol Biol Phys 2005 0.75
41 Modeling prostate cancer: in regards to Nahum et al. (Int J Radiat Oncol Biol Phys 2003;57:391-401). Int J Radiat Oncol Biol Phys 2005 0.75
42 Correlation between dose subfractions: in regard to Tome et al. [Radiother Oncol 2004;72:113-114]. Radiother Oncol 2005 0.75
43 Tumor hypoxia versus blood flow: In regard to Lehtio et al. (Int J Radiat Oncol Biol Phys 2004;59:971-982). Int J Radiat Oncol Biol Phys 2005 0.75
44 Synthesizing knowledge in the classroom. Science 2009 0.75
45 Imaging changes after stereotactic body radiation therapy for lung and liver tumors. Expert Rev Anticancer Ther 2011 0.75